

JCOG Progress Report to ATC

Satoshi Ishikura, M.D., Ph.D.

**JCOG Radiation Therapy Study Group/
Radiotherapy Support Center**

A phase II study of stereotactic body radiation therapy in patients with T1N0M0 non-small cell lung cancer (JCOG 0403)

- To evaluate the safety and efficacy of stereotactic body radiation therapy (SBRT) for T1N0M0 NSCLC
- Primary endpoint: 3-year overall survival
- Sample size : 175
 - Operable, 75 (completed); Inoperable, 100
 - Accrual will be completed in 2008

Patient Accrual

As of 1/23/2007

➤ # of enrolled pts	111
➤ # of submitted	104
➤ # of reviewed	104

A phase I dose escalation study of stereotactic body radiation therapy in patients with T2N0M0 non-small cell lung cancer (JCOG 070X)

- To define the recommended dose of stereotactic body radiation therapy (SBRT) for T2N0M0 NSCLC
- Primary endpoint: Grade ≥ 2 pneumonitis
- Sample size : 50-60 pts.
 - Inoperative or “unfit” for surgery
 - Accrual: 2-3 years